{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T10:35:36Z","timestamp":1781260536748,"version":"3.54.1"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-03868-3","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T05:19:11Z","timestamp":1741238351000},"page":"3511-3529","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["HPV-driven cancer: from epidemiology to the HPV-driven tumor board proposal, everything you wanted to know but were afraid to ask"],"prefix":"10.1007","volume":"27","author":[{"given":"Daniela","family":"Alterio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Gola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4655-4634","authenticated-orcid":false,"given":"Mattia","family":"Zaffaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giulia","family":"Vincini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Guglielmo","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Aristei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Macchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitaliana","family":"De Sanctis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"DeFelice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"issue":"3","key":"3868_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"3868_CR2","doi-asserted-by":"publisher","first-page":"864","DOI":"10.20892\/j.issn.2095-3941.2020.0370","volume":"17","author":"KA Szymonowicz","year":"2020","unstructured":"Szymonowicz KA, Chen J. Biological and clinical aspects of HPV-related cancers. Cancer Biol Med. 2020;17(4):864\u201378.","journal-title":"Cancer Biol Med"},{"issue":"1","key":"3868_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41392-024-02083-w","volume":"10","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Qiu K, Ren J, Zhao Y, Cheng P. Roles of human papillomavirus in cancers: oncogenic mechanisms and clinical use. Signal Transduct Target Ther. 2025;10(1):44.","journal-title":"Signal Transduct Target Ther"},{"issue":"4 Suppl","key":"3868_CR4","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.jadohealth.2010.01.016","volume":"46","author":"AK Chaturvedi","year":"2010","unstructured":"Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health. 2010;46(4 Suppl):S20-26.","journal-title":"J Adolesc Health"},{"key":"3868_CR5","unstructured":"Agents classified by the <em>IARC Monographs<\/em>, volumes 1\u2013135 [Internet]. [citato 24 maggio 2024]. Disponibile su: https:\/\/monographs.iarc.who.int\/agents-classified-by-the-iarc."},{"issue":"4","key":"3868_CR6","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.30716","volume":"141","author":"C de Martel","year":"2017","unstructured":"de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664\u201370.","journal-title":"Int J Cancer"},{"key":"3868_CR7","unstructured":"CDC. Centers for Disease Control and Prevention. 2023 [citato 24 maggio 2024]. HPV can cause certain cancers in men and women. Disponibile su: https:\/\/www.cdc.gov\/hpv\/parents\/cancer.html."},{"issue":"5","key":"3868_CR8","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.eururo.2015.12.007","volume":"69","author":"L Alemany","year":"2016","unstructured":"Alemany L, Cubilla A, Halec G, Kasamatsu E, Quir\u00f3s B, Masferrer E, et al. Role of human papillomavirus in penile carcinomas worldwide. Eur Urol. 2016;69(5):953\u201361.","journal-title":"Eur Urol"},{"issue":"6","key":"3868_CR9","doi-asserted-by":"publisher","first-page":"djv403","DOI":"10.1093\/jnci\/djv403","volume":"108","author":"X Castellsagu\u00e9","year":"2016","unstructured":"Castellsagu\u00e9 X, Alemany L, Quer M, Halec G, Quir\u00f3s B, Tous S, et al. HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst. 2016;108(6):djv403.","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"3868_CR10","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/j.ejca.2015.06.001","volume":"51","author":"B Serrano","year":"2015","unstructured":"Serrano B, de Sanjos\u00e9 S, Tous S, Quiros B, Mu\u00f1oz N, Bosch X, et al. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer. 2015;51(13):1732\u201341.","journal-title":"Eur J Cancer"},{"key":"3868_CR11","unstructured":"Halperin; Brady; Perez\u2014LIPPINCOTT Williams and Wilkins. Perez & Brady\u2019s principles and practice of radiation oncology, 6th edn. [Internet]. [citato 24 maggio 2024]. Disponibile su: https:\/\/www.medicalinformation.it\/perez-brady-s-principles-and-practice-of-radiation-oncology-6ed-halperin-edward-c-brady-luther-w-perez-carlos-a-wazer-david-e-lippincott-williams-and-wilkins-9781451116489.html."},{"issue":"Suppl 1","key":"3868_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/ijgo.13865","volume":"155","author":"N Bhatla","year":"2021","unstructured":"Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet. 2021;155(Suppl 1):28\u201344.","journal-title":"Int J Gynaecol Obstet"},{"key":"3868_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13027-016-0107-4","volume":"11","author":"R Senapati","year":"2016","unstructured":"Senapati R, Senapati NN, Dwibedi B. Molecular mechanisms of HPV mediated neoplastic progression. Infect Agent Cancer. 2016;11:59.","journal-title":"Infect Agent Cancer"},{"issue":"8","key":"3868_CR14","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/cid\/ciy1081","volume":"69","author":"H Mehanna","year":"2019","unstructured":"Mehanna H, Bryant TS, Babrah J, Louie K, Bryant JL, Spruce RJ, et al. Human papillomavirus (HPV) vaccine effectiveness and potential herd immunity for reducing oncogenic oropharyngeal HPV-16 prevalence in the united kingdom: a cross-sectional study. Clin Infect Dis. 2019;69(8):1296\u2013302.","journal-title":"Clin Infect Dis"},{"key":"3868_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.oraloncology.2017.04.013","volume":"69","author":"JS Torres-Roman","year":"2017","unstructured":"Torres-Roman JS, Aza\u00f1edo D, Ruiz EF, Avilez JL, M\u00e1laga G, Machicado C. Human papillomavirus-associated oropharyngeal cancer: prioritizing preventive policies in males. Oral Oncol. 2017;69:129\u201330.","journal-title":"Oral Oncol"},{"key":"3868_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.oraloncology.2019.04.001","volume":"93","author":"F De Felice","year":"2019","unstructured":"De Felice F, Polimeni A, Tombolini V. Human papillomavirus (HPV) vaccine and HPV-related head and neck cancer: what\u2019s next? Oral Oncol. 2019;93:125\u20136.","journal-title":"Oral Oncol"},{"issue":"2","key":"3868_CR17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41416-024-02655-1","volume":"131","author":"H Tabatabaeian","year":"2024","unstructured":"Tabatabaeian H, Bai Y, Huang R, Chaurasia A, Darido C. Navigating therapeutic strategies: HPV classification in head and neck cancer. Br J Cancer. 2024;131(2):220\u201330.","journal-title":"Br J Cancer"},{"issue":"8","key":"3868_CR18","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/v9080206","volume":"9","author":"TR Litwin","year":"2017","unstructured":"Litwin TR, Clarke MA, Dean M, Wentzensen N. Somatic host cell alterations in HPV carcinogenesis. Viruses. 2017;9(8):206.","journal-title":"Viruses"},{"key":"3868_CR19","unstructured":"NCCN [Internet]. [citato 11 ottobre 2024]. Treatment by cancer type. Disponibile su: https:\/\/www.nccn.org\/guidelines\/category_1."},{"issue":"1","key":"3868_CR20","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ijrobp.2014.09.023","volume":"91","author":"AJ Bishop","year":"2015","unstructured":"Bishop AJ, Allen PK, Klopp AH, Meyer LA, Eifel PJ. Relationship between low hemoglobin levels and outcomes after treatment with radiation or chemoradiation in patients with cervical cancer: has the impact of anemia been overstated? Int J Radiat Oncol Biol Phys. 2015;91(1):196\u2013205.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"3868_CR21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12905-023-02713-5","volume":"23","author":"X Wang","year":"2023","unstructured":"Wang X, Xu J, Zhang H, Qu P. The effect of albumin and hemoglobin levels on the prognosis of early-stage cervical cancer: a prospective, single-center-based cohort study. BMC Womens Health. 2023;23(1):553.","journal-title":"BMC Womens Health"},{"issue":"6","key":"3868_CR22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1080\/02841860600833160","volume":"45","author":"K Serkies","year":"2006","unstructured":"Serkies K, Badzio A, Jassem J. Clinical relevance of hemoglobin level in cervical cancer patients administered definitive radiotherapy. Acta Oncol. 2006;45(6):695\u2013701.","journal-title":"Acta Oncol"},{"issue":"16_suppl","key":"3868_CR23","doi-asserted-by":"publisher","first-page":"e17529","DOI":"10.1200\/JCO.2023.41.16_suppl.e17529","volume":"41","author":"MW Castro-Mollo","year":"2023","unstructured":"Castro-Mollo MW, Galvez-Nino M, Ruiz R, Roque K, Coanqui O, Valdivieso N, et al. Impact of hemoglobin on survival of young women with cervical cancer treated with concurrent chemoradiotherapy. JCO. 2023;41(16_suppl):e17529\u2013e17529.","journal-title":"JCO"},{"key":"3868_CR24","unstructured":"D\u00edaz JFR. Hemoglobin level and survival in cervical cancer with chemoradiotherapy at high altitude, 2020\u20132022. 13 settembre 2024 [citato 11 ottobre 2024]; Disponibile su: http:\/\/ecancer.org\/en\/journal\/article\/1767-hemoglobin-level-and-survival-in-cervical-cancer-with-chemoradiotherapy-at-high-altitude-2020-2022\/abstract."},{"issue":"4","key":"3868_CR25","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1097\/IGC.0b013e31828a0623","volume":"23","author":"M Barkati","year":"2013","unstructured":"Barkati M, Fortin I, Mileshkin L, Bernshaw D, Carrier JF, Narayan K. Hemoglobin level in cervical cancer: a surrogate for an infiltrative phenotype. Int J Gynecol Cancer. 2013;23(4):724\u20139.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"3868_CR26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.ygyno.2004.04.008","volume":"94","author":"WE Winter","year":"2004","unstructured":"Winter WE, Maxwell GL, Tian C, Sobel E, Rose GS, Thomas G, et al. Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: a Gynecologic Oncology Group Study. Gynecol Oncol. 2004;94(2):495\u2013501.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"3868_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ygyno.2007.08.086","volume":"108","author":"LC Horn","year":"2008","unstructured":"Horn LC, Hentschel B, Galle D, Bilek K. Extracapsular extension of pelvic lymph node metastases is of prognostic value in carcinoma of the cervix uteri. Gynecol Oncol. 2008;108(1):63\u20137.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"3868_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/ijgc-2021-003014","volume":"32","author":"A Fernandes","year":"2022","unstructured":"Fernandes A, Viveros-Carre\u00f1o D, Hoegl J, \u00c1vila M, Pareja R. Human papillomavirus-independent cervical cancer. Int J Gynecol Cancer. 2022;32(1):1\u20137.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"3868_CR29","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12916-023-02965-w","volume":"21","author":"SJ Bowden","year":"2023","unstructured":"Bowden SJ, Doulgeraki T, Bouras E, Markozannes G, Athanasiou A, Grout-Smith H, et al. Risk factors for human papillomavirus infection, cervical intraepithelial neoplasia and cervical cancer: an umbrella review and follow-up Mendelian randomisation studies. BMC Med. 2023;21(1):274.","journal-title":"BMC Med"},{"key":"3868_CR30","doi-asserted-by":"publisher","first-page":"1114042","DOI":"10.3389\/fonc.2023.1114042","volume":"13","author":"Y Li","year":"2023","unstructured":"Li Y, Gao X, Huang Y, Zhu X, Chen Y, Xue L, et al. Tumor microenvironment promotes lymphatic metastasis of cervical cancer: its mechanisms and clinical implications. Front Oncol. 2023;13:1114042.","journal-title":"Front Oncol"},{"issue":"4","key":"3868_CR31","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.3390\/cancers15041137","volume":"15","author":"A Santoro","year":"2023","unstructured":"Santoro A, Inzani F, Angelico G, Arciuolo D, Bragantini E, Travaglino A, et al. Recent advances in cervical cancer management: a review on novel prognostic factors in primary and recurrent tumors. Cancers (Basel). 2023;15(4):1137.","journal-title":"Cancers (Basel)."},{"issue":"3","key":"3868_CR32","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00404-022-06687-x","volume":"307","author":"M Gultekin","year":"2023","unstructured":"Gultekin M, Beduk Esen CS, Ates Ozdemir D, Yildirim S, Yuce D, Usubutun A, et al. Stromal or intraepithelial tumor-infiltrating lymphocytes: which one has more prognostic significance in cervical cancer? Arch Gynecol Obstet. 2023;307(3):969\u201380.","journal-title":"Arch Gynecol Obstet"},{"key":"3868_CR33","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.omto.2021.07.006","volume":"22","author":"Y Tang","year":"2021","unstructured":"Tang Y, Zhang AXJ, Chen G, Wu Y, Gu W. Prognostic and therapeutic TILs of cervical cancer\u2014current advances and future perspectives. Mol Ther Oncol. 2021;22:410\u201330.","journal-title":"Mol Ther Oncol"},{"issue":"14","key":"3868_CR34","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","volume":"33","author":"S Stevanovi\u0107","year":"2015","unstructured":"Stevanovi\u0107 S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015;33(14):1543\u201350.","journal-title":"J Clin Oncol"},{"key":"3868_CR35","doi-asserted-by":"publisher","first-page":"8345235","DOI":"10.1155\/2020\/8345235","volume":"2020","author":"H Yin","year":"2020","unstructured":"Yin H, Guo W, Sun X, Li R, Feng C, Tan Y. TILs and anti-PD1 therapy: an alternative combination therapy for PDL1 negative metastatic cervical cancer. J Immunol Res. 2020;2020:8345235.","journal-title":"J Immunol Res"},{"issue":"2","key":"3868_CR36","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ygyno.2020.07.106","volume":"159","author":"A Ohno","year":"2020","unstructured":"Ohno A, Iwata T, Katoh Y, Taniguchi S, Tanaka K, Nishio H, et al. Tumor-infiltrating lymphocytes predict survival outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy. Gynecol Oncol. 2020;159(2):329\u201334.","journal-title":"Gynecol Oncol"},{"issue":"10","key":"3868_CR37","doi-asserted-by":"publisher","first-page":"16755","DOI":"10.18632\/oncotarget.15157","volume":"8","author":"QT Huang","year":"2017","unstructured":"Huang QT, Man QQ, Hu J, Yang YL, Zhang YM, Wang W, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in cervical cancer: a systematic review and meta-analysis of observational studies. Oncotarget. 2017;8(10):16755\u201364.","journal-title":"Oncotarget"},{"issue":"4","key":"3868_CR38","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.23.00954","volume":"42","author":"K Han","year":"2024","unstructured":"Han K, Zou J, Zhao Z, Baskurt Z, Zheng Y, Barnes E, et al. Clinical validation of human papilloma virus circulating tumor DNA for early detection of residual disease after chemoradiation in cervical cancer. J Clin Oncol. 2024;42(4):431\u201340.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3868_CR39","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12935-023-03132-0","volume":"23","author":"L Li","year":"2023","unstructured":"Li L, Tong Y, Wu J, Xu X. Clinical applications and utility of ctDNA in cervical cancer and its precursor lesions: from screening to predictive biomarker. Cancer Cell Int. 2023;23(1):329.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"3868_CR40","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.radonc.2017.10.018","volume":"126","author":"P Lassen","year":"2018","unstructured":"Lassen P, Lacas B, Pignon JP, Trotti A, Zackrisson B, Zhang Q, et al. Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: the MARCH-HPV project. Radiother Oncol. 2018;126(1):107\u201315.","journal-title":"Radiother Oncol"},{"issue":"8","key":"3868_CR41","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1002\/ijc.22851","volume":"121","author":"CCR Ragin","year":"2007","unstructured":"Ragin CCR, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer. 2007;121(8):1813\u201320.","journal-title":"Int J Cancer"},{"key":"3868_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.oraloncology.2016.01.002","volume":"54","author":"PP Sedghizadeh","year":"2016","unstructured":"Sedghizadeh PP, Billington WD, Paxton D, Ebeed R, Mahabady S, Clark GT, et al. Is p16-positive oropharyngeal squamous cell carcinoma associated with favorable prognosis? A systematic review and meta-analysis. Oral Oncol. 2016;54:15\u201327.","journal-title":"Oral Oncol"},{"key":"3868_CR43","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.oraloncology.2016.09.005","volume":"62","author":"G D\u2019Souza","year":"2016","unstructured":"D\u2019Souza G, Anantharaman D, Gheit T, Abedi-Ardekani B, Beachler DC, Conway DI, et al. Effect of HPV on head and neck cancer patient survival, by region and tumor site: a comparison of 1362 cases across three continents. Oral Oncol. 2016;62:20\u20137.","journal-title":"Oral Oncol"},{"issue":"15","key":"3868_CR44","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1016\/j.ejca.2014.07.001","volume":"50","author":"L Masterson","year":"2014","unstructured":"Masterson L, Moualed D, Liu ZW, Howard JEF, Dwivedi RC, Tysome JR, et al. De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials. Eur J Cancer. 2014;50(15):2636\u201348.","journal-title":"Eur J Cancer"},{"issue":"15","key":"3868_CR45","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1056\/NEJMoa1514493","volume":"374","author":"H Mehanna","year":"2016","unstructured":"Mehanna H, Wong WL, McConkey CC, Rahman JK, Robinson M, Hartley AGJ, et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. N Engl J Med. 2016;374(15):1444\u201354.","journal-title":"N Engl J Med"},{"key":"3868_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.106054","volume":"133","author":"SJ Ma","year":"2022","unstructured":"Ma SJ, Yu H, Khan M, Yu B, Santhosh S, Chatterjee U, et al. Defining the optimal threshold and prognostic utility of pre-treatment hemoglobin level as a biomarker for survival outcomes in head and neck cancer patients receiving chemoradiation. Oral Oncol. 2022;133: 106054.","journal-title":"Oral Oncol"},{"key":"3868_CR47","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pvr.2017.12.002","volume":"5","author":"P Gorphe","year":"2018","unstructured":"Gorphe P, Chekkoury Idrissi Y, Tao Y, Schernberg A, Ou D, Temam S, et al. Anemia and neutrophil-to-lymphocyte ratio are prognostic in p16-positive oropharyngeal carcinoma treated with concurrent chemoradiation. Papillomavirus Res. 2018;5:32\u20137.","journal-title":"Papillomavirus Res"},{"issue":"1","key":"3868_CR48","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hed.24528","volume":"39","author":"P Baumeister","year":"2017","unstructured":"Baumeister P, Rauch J, Jacobi C, Kisser U, Betz C, Becker S, et al. Impact of comorbidity and anemia in patients with oropharyngeal cancer primarily treated with surgery in the human papillomavirus era. Head Neck. 2017;39(1):7\u201316.","journal-title":"Head Neck"},{"issue":"7","key":"3868_CR49","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3390\/cancers15072022","volume":"15","author":"S Volpe","year":"2023","unstructured":"Volpe S, Gaeta A, Colombo F, Zaffaroni M, Mastroleo F, Vincini MG, et al. Blood- and imaging-derived biomarkers for oncological outcome modelling in oropharyngeal cancer: exploring the low-hanging fruit. Cancers (Basel). 2023;15(7):2022.","journal-title":"Cancers (Basel)."},{"issue":"14","key":"3868_CR50","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1002\/cncr.26671","volume":"118","author":"P Sinha","year":"2012","unstructured":"Sinha P, Lewis JS, Piccirillo JF, Kallogjeri D, Haughey BH. Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma. Cancer. 2012;118(14):3519\u201330.","journal-title":"Cancer"},{"issue":"7","key":"3868_CR51","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamaoto.2016.0882","volume":"142","author":"N Kharytaniuk","year":"2016","unstructured":"Kharytaniuk N, Molony P, Boyle S, O\u2019Leary G, Werner R, Heffron C, et al. Association of extracapsular spread with survival according to human papillomavirus status in oropharynx squamous cell carcinoma and carcinoma of unknown primary site. JAMA Otolaryngol Head Neck Surg. 2016;142(7):683\u201390.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"4","key":"3868_CR52","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1177\/0194599820951176","volume":"164","author":"L Benchetrit","year":"2021","unstructured":"Benchetrit L, Torabi SJ, Givi B, Haughey B, Judson BL. Prognostic significance of extranodal extension in HPV-mediated oropharyngeal carcinoma: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2021;164(4):720\u201332.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"18","key":"3868_CR53","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1002\/cncr.28169","volume":"119","author":"JH Maxwell","year":"2013","unstructured":"Maxwell JH, Ferris RL, Gooding W, Cunningham D, Mehta V, Kim S, et al. Extracapsular spread in head and neck carcinoma: impact of site and human papillomavirus status. Cancer. 2013;119(18):3302\u20138.","journal-title":"Cancer"},{"issue":"Suppl 1","key":"3868_CR54","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1007\/s00405-007-0557-9","volume":"265","author":"J Klozar","year":"2008","unstructured":"Klozar J, Kratochvil V, Salakova M, Smahelova J, Vesela E, Hamsikova E, et al. HPV status and regional metastasis in the prognosis of oral and oropharyngeal cancer. Eur Arch Otorhinolaryngol. 2008;265(Suppl 1):S75-82.","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"3868_CR55","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.oraloncology.2017.09.014","volume":"74","author":"J Shevach","year":"2017","unstructured":"Shevach J, Bossert A, Bakst RL, Liu J, Misiukiewicz K, Beyda J, et al. Extracapsular extension is associated with worse distant control and progression-free survival in patients with lymph node-positive human papillomavirus-related oropharyngeal carcinoma. Oral Oncol. 2017;74:56\u201361.","journal-title":"Oral Oncol"},{"issue":"5","key":"3868_CR56","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/0003489417693014","volume":"126","author":"P Tassone","year":"2017","unstructured":"Tassone P, Crawley M, Bovenzi C, Zhan T, Keane W, Cognetti D, et al. Pathologic markers in surgically treated HPV-associated oropharyngeal cancer: retrospective study, systematic review, and meta-analysis. Ann Otol Rhinol Laryngol. 2017;126(5):365\u201374.","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"3868_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.oraloncology.2016.02.011","volume":"56","author":"A Amini","year":"2016","unstructured":"Amini A, Jasem J, Jones BL, Robin TP, McDermott JD, Bhatia S, et al. Predictors of overall survival in human papillomavirus-associated oropharyngeal cancer using the National Cancer Data Base. Oral Oncol. 2016;56:1\u20137.","journal-title":"Oral Oncol"},{"issue":"14","key":"3868_CR58","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1002\/cncr.30598","volume":"123","author":"Y An","year":"2017","unstructured":"An Y, Park HS, Kelly JR, Stahl JM, Yarbrough WG, Burtness BA, et al. The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma. Cancer. 2017;123(14):2762\u201372.","journal-title":"Cancer"},{"issue":"5","key":"3868_CR59","doi-asserted-by":"publisher","first-page":"102592","DOI":"10.1016\/j.amjoto.2020.102592","volume":"41","author":"SY Chen","year":"2020","unstructured":"Chen SY, Massa S, Mazul AL, Kallogjeri D, Yaeger L, Jackson RS, et al. The association of smoking and outcomes in HPV-positive oropharyngeal cancer: a systematic review. Am J Otolaryngol. 2020;41(5):102592.","journal-title":"Am J Otolaryngol"},{"issue":"1","key":"3868_CR60","doi-asserted-by":"publisher","first-page":"6071","DOI":"10.1038\/s41467-020-19822-6","volume":"11","author":"M Gormley","year":"2020","unstructured":"Gormley M, Dudding T, Sanderson E, Martin RM, Thomas S, Tyrrell J, et al. A multivariable Mendelian randomization analysis investigating smoking and alcohol consumption in oral and oropharyngeal cancer. Nat Commun. 2020;11(1):6071.","journal-title":"Nat Commun"},{"issue":"5","key":"3868_CR61","doi-asserted-by":"publisher","first-page":"103555","DOI":"10.1016\/j.amjoto.2022.103555","volume":"43","author":"K Schostag","year":"2022","unstructured":"Schostag K, Lynch PT, Leavitt T, Sumer BD, Yang A, Shah A, et al. Smoking and other patient factors in HPV-mediated oropharynx cancer: a retrospective cohort study. Am J Otolaryngol. 2022;43(5):103555.","journal-title":"Am J Otolaryngol"},{"issue":"4","key":"3868_CR62","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1177\/01945998211024515","volume":"166","author":"RH Lee","year":"2022","unstructured":"Lee RH, Salesky M, Benjamin T, El-Sayed IH, George JR, Ha PK, et al. Impact of smoking and primary tumor subsite on recurrence in HPV-associated oropharyngeal squamous cell carcinoma. Otolaryngol-Head Neck Surg. 2022;166(4):704\u201311.","journal-title":"Otolaryngol-Head Neck Surg"},{"issue":"2","key":"3868_CR63","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/hed.26001","volume":"42","author":"R Xiao","year":"2020","unstructured":"Xiao R, Pham Y, Ward MC, Houston N, Reddy CA, Joshi NP, et al. Impact of active smoking on outcomes in HPV+ oropharyngeal cancer. Head Neck. 2020;42(2):269\u201380.","journal-title":"Head Neck"},{"issue":"5","key":"3868_CR64","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/hed.26612","volume":"43","author":"HYH Liu","year":"2021","unstructured":"Liu HYH, Daniels CP, Trada Y, Bernard A, You KH, Brown E, et al. The importance of smoking status at diagnosis in human papillomavirus-associated oropharyngeal cancer. Head Neck. 2021;43(5):1440\u201350.","journal-title":"Head Neck"},{"issue":"3","key":"3868_CR65","doi-asserted-by":"publisher","first-page":"102915","DOI":"10.1016\/j.amjoto.2021.102915","volume":"42","author":"SY Chen","year":"2021","unstructured":"Chen SY, Last A, Ettyreddy A, Kallogjeri D, Wahle B, Chidambaram S, et al. 20 pack-year smoking history as strongest smoking metric predictive of HPV-positive oropharyngeal cancer outcomes. Am J Otolaryngol. 2021;42(3):102915.","journal-title":"Am J Otolaryngol"},{"issue":"2","key":"3868_CR66","first-page":"164","volume":"73","author":"JJ Kang","year":"2023","unstructured":"Kang JJ, Yu Y, Chen L, Zakeri K, Gelblum DY, McBride SM, et al. Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer. CA Cancer J Clin. 2023;73(2):164\u201397.","journal-title":"CA Cancer J Clin"},{"key":"3868_CR67","doi-asserted-by":"publisher","first-page":"104373","DOI":"10.1016\/j.ebiom.2022.104373","volume":"86","author":"PYF Zeng","year":"2022","unstructured":"Zeng PYF, Cecchini MJ, Barrett JW, Shammas-Toma M, De Cecco L, Serafini MS, et al. Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification. EBioMedicine. 2022;86:104373.","journal-title":"EBioMedicine"},{"issue":"2","key":"3868_CR68","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/bjc.2013.639","volume":"110","author":"MJ Ward","year":"2014","unstructured":"Ward MJ, Thirdborough SM, Mellows T, Riley C, Harris S, Suchak K, et al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br J Cancer. 2014;110(2):489\u2013500.","journal-title":"Br J Cancer"},{"issue":"10","key":"3868_CR69","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1200\/JCO.19.02444","volume":"38","author":"BS Chera","year":"2020","unstructured":"Chera BS, Kumar S, Shen C, Amdur R, Dagan R, Green R, et al. Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. J Clin Oncol. 2020;38(10):1050\u20138.","journal-title":"J Clin Oncol"},{"key":"3868_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.105776","volume":"126","author":"CT Haring","year":"2022","unstructured":"Haring CT, Dermody SM, Yalamanchi P, Kang SY, Old MO, Chad Brenner J, et al. The future of circulating tumor DNA as a biomarker in HPV related oropharyngeal squamous cell carcinoma. Oral Oncol. 2022;126: 105776.","journal-title":"Oral Oncol"},{"issue":"4","key":"3868_CR71","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1158\/1055-9965.EPI-19-1259","volume":"29","author":"A Urbute","year":"2020","unstructured":"Urbute A, Rasmussen CL, Belmonte F, Obermueller T, Prigge ES, Arbyn M, et al. Prognostic significance of HPV DNA and p16INK4a in anal cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev. 2020;29(4):703\u201310.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"10","key":"3868_CR72","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s00384-021-03910-0","volume":"36","author":"F Baidoun","year":"2021","unstructured":"Baidoun F, Saad AM, Abdel-Rahman O. The impact of gender and HPV status on anal squamous cell carcinoma survival. Int J Colorectal Dis. 2021;36(10):2093\u2013109.","journal-title":"Int J Colorectal Dis"},{"issue":"6","key":"3868_CR73","doi-asserted-by":"publisher","first-page":"998","DOI":"10.21037\/jgo.2017.10.05","volume":"8","author":"J Jhaveri","year":"2017","unstructured":"Jhaveri J, Rayfield L, Liu Y, Chowdhary M, Cassidy RJ, Madden NA, et al. Prognostic relevance of human papillomavirus infection in anal squamous cell carcinoma: analysis of the national cancer data base. J Gastrointest Oncol. 2017;8(6):998\u20131008.","journal-title":"J Gastrointest Oncol"},{"issue":"10","key":"3868_CR74","doi-asserted-by":"publisher","first-page":"e108790","DOI":"10.1371\/journal.pone.0108790","volume":"9","author":"GB Rold\u00e1n Urgoiti","year":"2014","unstructured":"Rold\u00e1n Urgoiti GB, Gustafson K, Klimowicz AC, Petrillo SK, Magliocco AM, Doll CM. The prognostic value of HPV status and p16 expression in patients with carcinoma of the anal canal. PLoS ONE. 2014;9(10):e108790.","journal-title":"PLoS ONE"},{"key":"3868_CR75","doi-asserted-by":"crossref","unstructured":"Ponce SEB, Erickson BA, Hall WA, Bedi M, Martens MJ, Siker M, et al. Long term clinical outcomes and associated predictors of progression free survival in anal canal cancer. J Gastrointest Oncol [Internet]. febbraio 2022 [citato 11 ottobre 2024];13(1). Disponibile su: https:\/\/jgo.amegroups.org\/article\/view\/60285.","DOI":"10.21037\/jgo-21-482"},{"issue":"3","key":"3868_CR76","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.ijrobp.2018.07.211","volume":"102","author":"SE Kelm","year":"2018","unstructured":"Kelm SE, Longo JM, Bedi M, Siker ML, Thomas J, George B, et al. The impact of hemoglobin on outcomes in anal canal cancer treated with definitive chemoradiation. Int J Radiat Oncol Biol Phys. 2018;102(3):e9.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"3868_CR77","doi-asserted-by":"publisher","first-page":"259","DOI":"10.5306\/wjco.v14.i7.259","volume":"14","author":"KR McMahon","year":"2023","unstructured":"McMahon KR, Gemma N, Clapp M, Sanchez-Montejo P, Dibello J, Laipply E. Relationship between anal cancer recurrence and cigarette smoking. World J Clin Oncol. 2023;14(7):259\u201364.","journal-title":"World J Clin Oncol."},{"key":"3868_CR78","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ejca.2020.09.039","volume":"141","author":"J Lerman","year":"2020","unstructured":"Lerman J, Hennequin C, Etienney I, Abramowitz L, Goujon G, Gornet JM, et al. Impact of tobacco smoking on the patient\u2019s outcome after (chemo)radiotherapy for anal cancer. Eur J Cancer. 2020;141:143\u201351.","journal-title":"Eur J Cancer"},{"issue":"1","key":"3868_CR79","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.bbcan.2017.05.001","volume":"1868","author":"D Martin","year":"2017","unstructured":"Martin D, R\u00f6del F, Balermpas P, R\u00f6del C, Fokas E. The immune microenvironment and HPV in anal cancer: rationale to complement chemoradiation with immunotherapy. Biochim Biophys Acta Rev Cancer. 2017;1868(1):221\u201330.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"2","key":"3868_CR80","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/bjc.2015.448","volume":"114","author":"DC Gilbert","year":"2016","unstructured":"Gilbert DC, Serup-Hansen E, Linnemann D, H\u00f8gdall E, Bailey C, Summers J, et al. Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer. Br J Cancer. 2016;114(2):134\u20137.","journal-title":"Br J Cancer"},{"issue":"3","key":"3868_CR81","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1288331","volume":"6","author":"P Balermpas","year":"2017","unstructured":"Balermpas P, Martin D, Wieland U, Rave-Fr\u00e4nk M, Strebhardt K, R\u00f6del C, et al. Human papilloma virus load and PD-1\/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: rationale for immunotherapy. Oncoimmunology. 2017;6(3): e1288331.","journal-title":"Oncoimmunology"},{"issue":"5","key":"3868_CR82","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.21037\/jgo-21-323","volume":"12","author":"B De","year":"2021","unstructured":"De B, Ludmir EB, Messick CA, Cagley MC, Morris VK, Das P, et al. Prognostic impact of lymphopenia and neutrophil-lymphocyte ratio for patients with anal squamous cell carcinoma. J Gastrointest Oncol. 2021;12(5):2412\u201322.","journal-title":"J Gastrointest Oncol"},{"issue":"24","key":"3868_CR83","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.21037\/atm-22-5935","volume":"10","author":"MQ Yang","year":"2022","unstructured":"Yang MQ, Liu YC, Sui JD, Jin F, Li D, Zhang L, et al. Reduced-dose radiation in human papillomavirus-associated oropharyngeal carcinoma can improve outcome: a systematic review and meta-analysis. Ann Transl Med. 2022;10(24):1391.","journal-title":"Ann Transl Med"},{"issue":"7","key":"3868_CR84","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.3390\/ijms25074005","volume":"25","author":"HC Temperley","year":"2024","unstructured":"Temperley HC, Fannon T, O\u2019Sullivan NJ, O\u2019Neill M, Mac Curtain BM, Gilham C, et al. Assessing circulating tumour DNA (ctDNA) as a biomarker for anal cancer management: a systematic review. Int J Mol Sci. 2024;25(7):4005.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"3868_CR85","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1136\/ijgc-2023-004589","volume":"33","author":"N Bizzarri","year":"2023","unstructured":"Bizzarri N, Russo L, Dolciami M, Zormpas-Petridis K, Boldrini L, Querleu D, et al. Radiomics systematic review in cervical cancer: gynecological oncologists\u2019 perspective. Int J Gynecol Cancer. 2023;33(10):1522\u201341.","journal-title":"Int J Gynecol Cancer"},{"key":"3868_CR86","doi-asserted-by":"publisher","unstructured":"Shang F, Tan Z, Gong T, Tang X, Sun H, Liu S. Evaluation of parametrial infiltration in patients with IB-IIB cervical cancer by a radiomics model integrating features from tumoral and peritumoral regions in 18 F-fluorodeoxy glucose positron emission tomography\/MR images. NMR Biomed. 2023:e4945; https:\/\/doi.org\/10.1002\/nbm.4945. Epub ahead of print. PMID: 37012600","DOI":"10.1002\/nbm.4945"},{"key":"3868_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109489","volume":"182","author":"Z Le","year":"2023","unstructured":"Le Z, Wu D, Chen X, Wang L, Xu Y, Zhao G, et al. A radiomics approach for predicting acute hematologic toxicity in patients with cervical or endometrial cancer undergoing external-beam radiotherapy. Radiother Oncol. 2023;182: 109489.","journal-title":"Radiother Oncol"},{"key":"3868_CR88","doi-asserted-by":"publisher","first-page":"1252074","DOI":"10.3389\/fonc.2023.1252074","volume":"13","author":"S Wang","year":"2023","unstructured":"Wang S, Liu X, Wu Y, Jiang C, Luo Y, Tang X, et al. Habitat-based radiomics enhances the ability to predict lymphovascular space invasion in cervical cancer: a multi-center study. Front Oncol. 2023;13:1252074.","journal-title":"Front Oncol"},{"issue":"5","key":"3868_CR89","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/s00259-012-2332-4","volume":"40","author":"F Yang","year":"2013","unstructured":"Yang F, Thomas MA, Dehdashti F, Grigsby PW. Temporal analysis of intratumoral metabolic heterogeneity characterized by textural features in cervical cancer. Eur J Nucl Med Mol Imaging. 2013;40(5):716\u201327.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"3868_CR90","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/odi.14386","volume":"30","author":"P Wang","year":"2024","unstructured":"Wang P, Wang X, Zhang M, Li G, Zhao N, Qiao Q. Combining the radiomics signature and HPV status for the risk stratification of patients with OPC. Oral Dis. 2024;30(2):272\u201380.","journal-title":"Oral Dis"},{"issue":"22","key":"3868_CR91","doi-asserted-by":"publisher","first-page":"5689","DOI":"10.3390\/cancers13225689","volume":"13","author":"B Rich","year":"2021","unstructured":"Rich B, Huang J, Yang Y, Jin W, Johnson P, Wang L, et al. Radiomics predicts for distant metastasis in locally advanced human papillomavirus-positive oropharyngeal squamous cell carcinoma. Cancers. 2021;13(22):5689.","journal-title":"Cancers"},{"issue":"1","key":"3868_CR92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41698-022-00342-z","volume":"7","author":"B Song","year":"2023","unstructured":"Song B, Yang K, Viswanathan VS, Wang X, Lee J, Stock S, et al. CT radiomic signature predicts survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma. NPJ Precis Oncol. 2023;7(1):1\u201313.","journal-title":"NPJ Precis Oncol."},{"issue":"4","key":"3868_CR93","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1177\/08465371231157592","volume":"74","author":"YS Chang","year":"2023","unstructured":"Chang YS, Nair JR, McDougall CC, Qiu W, Banerjee R, Joshi M, et al. Risk stratification for oropharyngeal squamous cell carcinoma using texture analysis on CT\u2014a step beyond HPV status. Can Assoc Radiol J. 2023;74(4):657\u201366.","journal-title":"Can Assoc Radiol J"},{"key":"3868_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2023.106307","volume":"137","author":"PA Boot","year":"2023","unstructured":"Boot PA, Mes SW, de Bloeme CM, Martens RM, Leemans CR, Boellaard R, et al. Magnetic resonance imaging based radiomics prediction of human papillomavirus infection status and overall survival in oropharyngeal squamous cell carcinoma. Oral Oncol. 2023;137: 106307.","journal-title":"Oral Oncol"},{"issue":"6","key":"3868_CR95","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.4149\/neo_2020_200310N249","volume":"67","author":"C Giannitto","year":"2020","unstructured":"Giannitto C, Marvaso G, Botta F, Raimondi S, Alterio D, Ciardo D, et al. Association of quantitative MRI-based radiomic features with prognostic factors and recurrence rate in oropharyngeal squamous cell carcinoma. Neoplasma. 2020;67(6):1437\u201346.","journal-title":"Neoplasma"},{"issue":"14","key":"3868_CR96","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.3390\/cancers15143715","volume":"15","author":"DA Garcia","year":"2023","unstructured":"Garcia DA, Jeans EB, Morris LK, Shiraishi S, Laughlin BS, Rong Y, et al. A radiomics-based classifier for the progression of oropharyngeal cancer treated with definitive radiotherapy. Cancers (Basel). 2023;15(14):3715.","journal-title":"Cancers (Basel)."},{"issue":"4","key":"3868_CR97","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/hed.26979","volume":"44","author":"YM Park","year":"2022","unstructured":"Park YM, Lim JY, Koh YW, Kim SH, Choi EC. Machine learning and magnetic resonance imaging radiomics for predicting human papilloma virus status and prognostic factors in oropharyngeal squamous cell carcinoma. Head Neck. 2022;44(4):897\u2013903.","journal-title":"Head Neck"},{"key":"3868_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2021.109701","volume":"139","author":"P Bos","year":"2021","unstructured":"Bos P, van den Brekel MWM, Gouw ZAR, Al-Mamgani A, Taghavi M, Waktola S, et al. Improved outcome prediction of oropharyngeal cancer by combining clinical and MRI features in machine learning models. Eur J Radiol. 2021;139: 109701.","journal-title":"Eur J Radiol"},{"issue":"7","key":"3868_CR99","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.3390\/cancers14071674","volume":"14","author":"W Lv","year":"2022","unstructured":"Lv W, Xu H, Han X, Zhang H, Ma J, Rahmim A, et al. Context-aware saliency guided radiomics: application to prediction of outcome and HPV-status from multi-center PET\/CT images of head and neck cancer. Cancers (Basel). 2022;14(7):1674.","journal-title":"Cancers (Basel)."},{"issue":"7","key":"3868_CR100","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.3390\/cancers12071778","volume":"12","author":"SP Haider","year":"2020","unstructured":"Haider SP, Zeevi T, Baumeister P, Reichel C, Sharaf K, Forghani R, et al. Potential added value of PET\/CT radiomics for survival prognostication beyond AJCC 8th edition staging in oropharyngeal squamous cell carcinoma. Cancers (Basel). 2020;12(7):1778.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"3868_CR101","doi-asserted-by":"publisher","first-page":"7198","DOI":"10.1038\/s41598-023-34162-3","volume":"13","author":"RTH Leijenaar","year":"2023","unstructured":"Leijenaar RTH, Walsh S, Vaidyanathan A, Aliboni L, Sanchez VL, Leech M, et al. External validation of a radiomic signature to predict p16 (HPV) status from standard CT images of anal cancer patients. Sci Rep. 2023;13(1):7198.","journal-title":"Sci Rep"},{"issue":"1097","key":"3868_CR102","doi-asserted-by":"publisher","first-page":"20181006","DOI":"10.1259\/bjr.20181006","volume":"92","author":"E Rusten","year":"2019","unstructured":"Rusten E, Rekstad BL, Undseth C, Klotz D, Hernes E, Guren MG, et al. Anal cancer chemoradiotherapy outcome prediction using 18F-fluorodeoxyglucose positron emission tomography and clinicopathological factors. Br J Radiol. 2019;92(1097):20181006.","journal-title":"Br J Radiol"},{"key":"3868_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109682","volume":"184","author":"D Cibula","year":"2023","unstructured":"Cibula D, Rosaria Raspollini M, Planchamp F, Centeno C, Chargari C, Felix A, et al. ESGO\/ESTRO\/ESP guidelines for the management of patients with cervical cancer\u2014update 2023. Radiother Oncol. 2023;184: 109682.","journal-title":"Radiother Oncol"},{"issue":"11","key":"3868_CR104","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","volume":"31","author":"JP Machiels","year":"2020","unstructured":"Machiels JP, Ren\u00e9 Leemans C, Golusinski W, Grau C, Licitra L, Gregoire V, et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1462\u201375.","journal-title":"Ann Oncol"},{"issue":"4","key":"3868_CR105","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/cncr.27825","volume":"119","author":"R Glynne-Jones","year":"2013","unstructured":"Glynne-Jones R, Sebag-Montefiore D, Adams R, Gollins S, Harrison M, Meadows HM, et al. Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I). Cancer. 2013;119(4):748\u201355.","journal-title":"Cancer"},{"issue":"8","key":"3868_CR106","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/ijc.33876","volume":"150","author":"P Lassen","year":"2022","unstructured":"Lassen P, Huang SH, Su J, Waldron J, Andersen M, Primdahl H, et al. Treatment outcomes and survival following definitive (chemo)radiotherapy in HPV-positive oropharynx cancer: large-scale comparison of DAHANCA vs PMH cohorts. Int J Cancer. 2022;150(8):1329\u201340.","journal-title":"Int J Cancer"},{"issue":"3","key":"3868_CR107","first-page":"318","volume":"22","author":"SK Gul","year":"2023","unstructured":"Gul SK, Tepetam H, Yildiz F, Er I, Oksuz DC, Parvizi M, et al. Revisiting the radical radiotherapy-radiochemotherapy results in anal canal cancers: (TROD Gastrointestinal Group Study 02\u2013005). Clin Colorectal Cancer. 2023;22(3):318\u201326.","journal-title":"Clin Colorectal Cancer"},{"issue":"5","key":"3868_CR108","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"H Bartelink","year":"1997","unstructured":"Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15(5):2040\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3868_CR109","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/jama.1995.03530050035029","volume":"274","author":"M Rotman","year":"1995","unstructured":"Rotman M, Pajak TF, Choi K, Clery M, Marcial V, Grigsby PW, et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79\u201320. JAMA. 1995;274(5):387\u201393.","journal-title":"JAMA"},{"issue":"5","key":"3868_CR110","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1200\/JCO.2004.07.197","volume":"22","author":"PJ Eifel","year":"2004","unstructured":"Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004;22(5):872\u201380.","journal-title":"J Clin Oncol"},{"issue":"19","key":"3868_CR111","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1200\/JCO.2006.09.4532","volume":"25","author":"PG Rose","year":"2007","unstructured":"Rose PG, Ali S, Watkins E, Thigpen JT, Deppe G, Clarke-Pearson DL, et al. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(19):2804\u201310.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3868_CR112","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/jjco\/hyg069","volume":"33","author":"T Inoue","year":"2003","unstructured":"Inoue T. The trail of the development of high-dose-rate brachytherapy for cervical cancer in Japan. Jpn J Clin Oncol. 2003;33(7):327\u201330.","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"3868_CR113","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ijrobp.2007.10.045","volume":"70","author":"T Toita","year":"2008","unstructured":"Toita T, Kodaira T, Shinoda A, Uno T, Akino Y, Mitsumori M, et al. Patterns of radiotherapy practice for patients with cervical cancer (1999\u20132001): patterns of care study in Japan. Int J Radiat Oncol Biol Phys. 2008;70(3):788\u201394.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"3868_CR114","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/jjco\/hyi142","volume":"35","author":"T Teshima","year":"2005","unstructured":"Teshima T, Japanes PCS Working Group. Patterns of care study in Japan. Jpn J Clin Oncol. 2005;35(9):497\u2013506.","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"3868_CR115","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.ijrobp.2003.11.032","volume":"59","author":"P Levendag","year":"2004","unstructured":"Levendag P, Nijdam W, Noever I, Schmitz P, van de Pol M, Sipkema D, et al. Brachytherapy versus surgery in carcinoma of tonsillar fossa and\/or soft palate: late adverse sequelae and performance status: can we be more selective and obtain better tissue sparing? Int J Radiat Oncol Biol Phys. 2004;59(3):713\u201324.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"3868_CR116","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/hed.20171","volume":"27","author":"O Karakoyun-Celik","year":"2005","unstructured":"Karakoyun-Celik O, Norris CM, Tishler R, Mahadevan A, Clark JR, Goldberg S, et al. Definitive radiotherapy with interstitial implant boost for squamous cell carcinoma of the tongue base. Head Neck. 2005;27(5):353\u201361.","journal-title":"Head Neck"},{"issue":"5","key":"3868_CR117","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.ijrobp.2023.08.056","volume":"118","author":"A Budrukkar","year":"2024","unstructured":"Budrukkar A, Murthy V, Kashid S, Swain M, Rangarajan V, Laskar SG, et al. Intensity-modulated radiation therapy alone versus intensity-modulated radiation therapy and brachytherapy for early-stage oropharyngeal cancers: results from a randomized controlled trial. Int J Radiat Oncol Biol Phys. 2024;118(5):1541\u201351.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"3868_CR118","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0167-8140(97)00192-8","volume":"46","author":"JP Gerard","year":"1998","unstructured":"Gerard JP, Ayzac L, Hun D, Romestaing P, Coquard R, Ardiet JM, et al. Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients. Radiother Oncol. 1998;46(3):249\u201356.","journal-title":"Radiother Oncol"},{"issue":"3","key":"3868_CR119","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0360-3016(97)00814-6","volume":"40","author":"AP Sandhu","year":"1998","unstructured":"Sandhu AP, Symonds RP, Robertson AG, Reed NS, McNee SG, Paul J. Interstitial iridium-192 implantation combined with external radiotherapy in anal cancer: ten years experience. Int J Radiat Oncol Biol Phys. 1998;40(3):575\u201381.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"3868_CR120","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13014-023-02256-x","volume":"18","author":"A Embring","year":"2023","unstructured":"Embring A, Onjukka E, Mercke C, Lax I, Berglund A, Friesland S. Dose escalation in oropharyngeal cancer: a comparison of simultaneous integrated boost and brachytherapy boost. Radiat Oncol. 2023;18(1):65.","journal-title":"Radiat Oncol"},{"issue":"1","key":"3868_CR121","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","volume":"92","author":"JP Pignon","year":"2009","unstructured":"Pignon JP, le Ma\u00eetre A, Maillard E, Bourhis J, MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4\u201314.","journal-title":"Radiother Oncol"},{"key":"3868_CR122","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.radonc.2021.01.013","volume":"156","author":"B Lacas","year":"2021","unstructured":"Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol. 2021;156:281\u201393.","journal-title":"Radiother Oncol"},{"issue":"5","key":"3868_CR123","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1200\/JCO.1999.17.5.1339","volume":"17","author":"CW Whitney","year":"1999","unstructured":"Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17(5):1339\u201348.","journal-title":"J Clin Oncol"},{"issue":"15","key":"3868_CR124","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1056\/NEJM199904153401502","volume":"340","author":"PG Rose","year":"1999","unstructured":"Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144\u201353.","journal-title":"N Engl J Med"},{"issue":"15","key":"3868_CR125","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1056\/NEJM199904153401503","volume":"340","author":"HM Keys","year":"1999","unstructured":"Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340(15):1154\u201361.","journal-title":"N Engl J Med"},{"issue":"8","key":"3868_CR126","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1200\/JCO.2000.18.8.1606","volume":"18","author":"WA Peters","year":"2000","unstructured":"Peters WA, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18(8):1606\u201313.","journal-title":"J Clin Oncol"},{"issue":"15","key":"3868_CR127","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1056\/NEJM199904153401501","volume":"340","author":"M Morris","year":"1999","unstructured":"Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340(15):1137\u201343.","journal-title":"N Engl J Med"},{"issue":"10","key":"3868_CR128","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1002\/1097-0142(19830515)51:10<1826::AID-CNCR2820511012>3.0.CO;2-L","volume":"51","author":"ND Nigro","year":"1983","unstructured":"Nigro ND, Seydel HG, Considine B, Vaitkevicius VK, Leichman L, Kinzie JJ. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer. 1983;51(10):1826\u20139.","journal-title":"Cancer"},{"key":"3868_CR129","unstructured":"National Institutes of Health (NIH) [Internet]. 2015 [citato 24 maggio 2024]. National Cancer Institute (NCI). Disponibile su: https:\/\/www.nih.gov\/about-nih\/what-we-do\/nih-almanac\/national-cancer-institute-nci."},{"key":"3868_CR130","doi-asserted-by":"publisher","first-page":"S1279","DOI":"10.1016\/j.annonc.2023.10.032","volume":"34","author":"D Lorusso","year":"2023","unstructured":"Lorusso D, Xiang Y, Hasegawa K, Scambia G, Galves MHL, Elias PR, et al. LBA38 pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: a randomized, double-blind, phase III ENGOT-cx11\/GOG-3047\/KEYNOTE-A18 study. Ann Oncol. 2023;34:S1279\u201380.","journal-title":"Ann Oncol"},{"issue":"2","key":"3868_CR131","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ijrobp.2009.06.014","volume":"75","author":"SA Eschrich","year":"2009","unstructured":"Eschrich SA, Pramana J, Zhang H, Zhao H, Boulware D, Lee JH, et al. A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys. 2009;75(2):489\u201396.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"3868_CR132","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41525-021-00200-0","volume":"6","author":"YH Dai","year":"2021","unstructured":"Dai YH, Wang YF, Shen PC, Lo CH, Yang JF, Lin CS, et al. Radiosensitivity index emerges as a potential biomarker for combined radiotherapy and immunotherapy. NPJ Genom Med. 2021;6(1):40.","journal-title":"NPJ Genom Med"},{"issue":"9","key":"3868_CR133","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/S1470-2045(21)00347-8","volume":"22","author":"JG Scott","year":"2021","unstructured":"Scott JG, Sedor G, Ellsworth P, Scarborough JA, Ahmed KA, Oliver DE, et al. Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis. Lancet Oncol. 2021;22(9):1221\u20139.","journal-title":"Lancet Oncol"},{"issue":"24","key":"3868_CR134","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.21037\/atm-22-5930","volume":"10","author":"Y Huang","year":"2022","unstructured":"Huang Y, Zou D, Guo M, He M, He H, Li X, et al. HPV and radiosensitivity of cervical cancer: a narrative review. Ann Transl Med. 2022;10(24):1405.","journal-title":"Ann Transl Med"},{"issue":"3","key":"3868_CR135","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.ijrobp.2022.03.006","volume":"113","author":"GD Grass","year":"2022","unstructured":"Grass GD, Alfonso JCL, Welsh E, Ahmed KA, Teer JK, Pilon-Thomas S, et al. The radiosensitivity index gene signature identifies distinct tumor immune microenvironment characteristics associated with susceptibility to radiation therapy. Int J Radiat Oncol Biol Phys. 2022;113(3):635\u201347.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3868_CR136","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ejca.2017.08.001","volume":"84","author":"T Strom","year":"2017","unstructured":"Strom T, Harrison LB, Giuliano AR, Schell MJ, Eschrich SA, Berglund A, et al. Tumour radiosensitivity is associated with immune activation in solid tumours. Eur J Cancer. 2017;84:304\u201314.","journal-title":"Eur J Cancer"},{"key":"3868_CR137","first-page":"PO.21.00094","volume":"5","author":"S Cavalieri","year":"2021","unstructured":"Cavalieri S, Serafini MS, Carenzo A, Canevari S, Brakenhoff RH, Leemans CR, et al. Clinical validity of a prognostic gene expression cluster-based model in human papillomavirus-positive oropharyngeal carcinoma. JCO Precis Oncol. 2021;5:PO.21.00094.","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"3868_CR138","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.clon.2023.02.018","volume":"35","author":"HB Mistry","year":"2023","unstructured":"Mistry HB. Radiosensitivity index is not fit to be used for dose adjustments: a pan-cancer analysis. Clin Oncol (R Coll Radiol). 2023;35(9):565\u201370.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"3868_CR139","unstructured":"Ho E, De Cecco L, Cavalieri S, Sedor G, Hoebers F, Brakenhoff RH, et al. A clinicogenomic model including GARD predicts outcome for radiation treated patients with HPV+ oropharyngeal squamous cell carcinoma. medRxiv. 14 settembre 2023. 2023.09.14.23295538."},{"issue":"6\u20137","key":"3868_CR140","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.canrad.2024.09.006","volume":"28","author":"G Camprodon","year":"2024","unstructured":"Camprodon G, Gabro A, El Ayachi Z, Chopra S, Nout R, Maingon P, et al. Personalized strategies for brachytherapy of cervix cancer. Cancer Radiother. 2024;28(6\u20137):610\u20137.","journal-title":"Cancer Radiother"},{"issue":"10","key":"3868_CR141","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1200\/JCO.22.01096","volume":"41","author":"MP Schmid","year":"2023","unstructured":"Schmid MP, Lindegaard JC, Mahantshetty U, Tanderup K, J\u00fcrgenliemk-Schulz I, Haie-Meder C, et al. Risk factors for local failure following chemoradiation and magnetic resonance image-guided brachytherapy in locally advanced cervical cancer: results from the EMBRACE-I study. J Clin Oncol. 2023;41(10):1933\u201342.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3868_CR142","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ijrobp.2018.06.014","volume":"102","author":"A Schernberg","year":"2018","unstructured":"Schernberg A, Bockel S, Annede P, Fumagalli I, Escande A, Mignot F, et al. Tumor shrinkage during chemoradiation in locally advanced cervical cancer patients: prognostic significance, and impact for image-guided adaptive brachytherapy. Int J Radiat Oncol Biol Phys. 2018;102(2):362\u201372.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"3868_CR143","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ygyno.2021.07.021","volume":"163","author":"N Murakami","year":"2021","unstructured":"Murakami N, Ando K, Murata M, Murata K, Ohno T, Aoshika T, et al. Why not de-intensification for uterine cervical cancer? Gynecol Oncol. 2021;163(1):105\u20139.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"3868_CR144","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ijrobp.2024.07.2316","volume":"121","author":"S Chopra","year":"2025","unstructured":"Chopra S, Bosse T, Horeweg N, Deodhar K, Menon S, Rafael T, et al. Biomarker expression and clinical outcomes in international study of chemoradiation and magnetic resonance imaging-based image-guided brachytherapy for locally advanced cervical cancer: BIOEMBRACE. Int J Radiat Oncol Biol Phys. 2025;121(1):97\u2013106.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"3868_CR145","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.radonc.2015.12.025","volume":"118","author":"K Kirchheiner","year":"2016","unstructured":"Kirchheiner K, Nout RA, Lindegaard JC, Haie-Meder C, Mahantshetty U, Segedin B, et al. Dose-effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study. Radiother Oncol. 2016;118(1):160\u20136.","journal-title":"Radiother Oncol"},{"issue":"6","key":"3868_CR146","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/jnci\/djaa184","volume":"113","author":"N Riaz","year":"2021","unstructured":"Riaz N, Sherman E, Pei X, Sch\u00f6der H, Grkovski M, Paudyal R, et al. Precision radiotherapy: reduction in radiation for oropharyngeal cancer in the 30 ROC trial. J Natl Cancer Inst. 2021;113(6):742\u201351.","journal-title":"J Natl Cancer Inst"},{"key":"3868_CR147","doi-asserted-by":"publisher","unstructured":"Byun DJ, Tam MM, Jacobson AS, Persky MS, Tran TT, Givi B, et al. Prognostic potential of mid-treatment nodal response in oropharyngeal squamous cell carcinoma. Head Neck. 2020 Sep 21. https:\/\/doi.org\/10.1002\/hed.26467. Epub ahead of print. PMID: 32964574; PMCID: PMC9879731","DOI":"10.1002\/hed.26467"},{"issue":"2, Supplement","key":"3868_CR148","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/j.ijrobp.2023.06.374","volume":"117","author":"JK Kim","year":"2023","unstructured":"Kim JK, Tam M, Karp JM, Oh C, Kim G, Solomon E, et al. A phase II trial evaluating rapid mid-treatment nodal shrinkage to select for adaptive deescalation in p16+ oropharyngeal cancer patients undergoing definitive chemoradiation. Int J Radiat Oncol Biol Phys. 2023;117(2, Supplement):S68\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3868_CR149","doi-asserted-by":"publisher","first-page":"1183854","DOI":"10.3389\/fonc.2023.1183854","volume":"13","author":"W Chu","year":"2023","unstructured":"Chu W, Taggar A, Ung Y, Chan KKW, Earle CC, Karotki A, et al. Risk-adjusted chemoradiation according to human papilloma viral status for anal cancer: a pilot study. Front Oncol. 2023;13:1183854.","journal-title":"Front Oncol"},{"issue":"4","key":"3868_CR150","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.semradonc.2021.02.007","volume":"31","author":"WT Turchan","year":"2021","unstructured":"Turchan WT, Liauw SL. Chemoradiation for anal cancer: clinical outcomes and strategies to optimize the therapeutic ratio according to HPV status. Semin Radiat Oncol. 2021;31(4):349\u201360.","journal-title":"Semin Radiat Oncol"},{"issue":"3","key":"3868_CR151","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3390\/cancers15030867","volume":"15","author":"AM Mazurek","year":"2023","unstructured":"Mazurek AM, Ma\u0142usecka E, Jab\u0142o\u0144ska I, Vydra N, Rutkowski TW, Giglok M, et al. Circulating HPV16 DNA in blood plasma as prognosticator and early indicator of cancer recurrence in radio-chemotherapy for anal cancer. Cancers (Basel). 2023;15(3):867.","journal-title":"Cancers (Basel)."},{"issue":"8","key":"3868_CR152","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1007\/s10147-023-02340-y","volume":"28","author":"N Egawa","year":"2023","unstructured":"Egawa N. Papillomaviruses and cancer: commonalities and differences in HPV carcinogenesis at different sites of the body. Int J Clin Oncol. 2023;28(8):956\u201364.","journal-title":"Int J Clin Oncol"},{"key":"3868_CR153","doi-asserted-by":"crossref","unstructured":"Sarier M. Association between human papillomavirus and urological cancers: an update. In: Molecular mechanisms in cancer [Internet]. IntechOpen; 2021 [citato 27 gennaio 2025]. Disponibile su: https:\/\/www.intechopen.com\/chapters\/79734.","DOI":"10.5772\/intechopen.101508"},{"issue":"1","key":"3868_CR154","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28208","volume":"95","author":"JX Sun","year":"2023","unstructured":"Sun JX, Xu JZ, Liu CQ, An Y, Xu MY, Zhong XY, et al. The association between human papillomavirus and bladder cancer: evidence from meta-analysis and two-sample mendelian randomization. J Med Virol. 2023;95(1): e28208.","journal-title":"J Med Virol"},{"issue":"1","key":"3868_CR155","first-page":"45","volume":"19","author":"M Sarier","year":"2021","unstructured":"Sarier M, Usta SS, Turgut H, \u00d6zt\u00fcrk SA, Soylu A, Emek M, et al. Prognostic value of HPV DNA in urothelial carcinoma of the bladder: a preliminary report of 2-year follow-up results. Urol J. 2021;19(1):45\u20139.","journal-title":"Urol J"},{"issue":"12","key":"3868_CR156","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1093\/annonc\/mdx528","volume":"28","author":"DL van der Velden","year":"2017","unstructured":"van der Velden DL, van Herpen CML, van Laarhoven HWM, Smit EF, Groen HJM, Willems SM, et al. Molecular Tumor Boards: current practice and future needs. Ann Oncol. 2017;28(12):3070\u20135.","journal-title":"Ann Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03868-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-03868-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03868-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T09:44:14Z","timestamp":1757151854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-03868-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":156,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["3868"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-03868-3","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Division of RT IEO received research funding from AIRC (Italian Association for Cancer Research), and Fondazione IEO-CCM (Istituto Europeo di Oncologia-Centro Cardiologico Monzino) (all outside the current project). IEO, the European Institute of Oncology IRCCS, was partially supported by institutional grants from Accuray Inc. and IBA (Ion Beam Applications, Louvain-la-Neuve, Belgium). The sponsors did not play any role in the study nor in the decision to submit the manuscript for publication. The remaining authors declare no conflicts of interest that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}